Fumiaki Mukohara

Fumiaki Mukohara

Auto-generated profile, based on publicly available information

Fumiaki Mukohara

Department of Tumor Microenvironment, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2025 in Cancer Research
Verified
Journal Article
Closed access
TNToshifumi Ninomiya
Toshifumi Ninomiya
NKNaoya Kemmotsu
Naoya Kemmotsu
FMFumiaki Mukohara
Fumiaki Mukohara
MMMasaki Magari
Masaki Magari
AMAi Miyamoto
Ai Miyamoto
YTYosuke Togashi
Yosuke Togashi
Brain metastasis is a poor prognostic factor in patients with cancer. Despite showing efficacy in many extracranial tumors, immunotherapy with anti–PD-1 mAb or anti–CTLA4 mAb seems to be less effective against intracranial tumors. Promisingly, recent clinical studies have reported that combination therapy with anti–PD-1 and anti–CTLA4 mAbs has a potent antitumor effect on brain metastasis, highlighting the need to elucidate the detailed mechanisms controlling the intracranial tumor microenvironment (TME) to develop effective immunotherapeutic strategies. In this study, we analyzed the tumor-infiltrating lymphocytes in murine models of brain metastasis that responded to anti–CTLA4 and anti–PD-1 mAbs. Activated CD4+ T follicular helper (TFH) cells with high CTLA4 expression characteristically infiltrated the intracranial TME, which were activated by combination anti–CTLA4 and anti–PD-1 treatment. The loss of TFH cells suppressed the additive effect of CTLA4 blockade on anti–PD-1 mAb. B-cell–activating factor belonging to the TNF family (BAFF) and a proliferation-inducing ligand (APRIL) produced by abundant myeloid cells, particularly CD80hiCD206lo proinflammatory M1-like macrophages, in the intracranial TME induced B-cell and TFH-cell infiltration and activation. Furthermore, the intracranial TME of patients with non–small cell lung cancer featured TFH- and B-cell infiltration as tertiary lymphoid structures. Together, these findings provide insights into the immune cell cross-talk in the intracranial TME that facilitates an additive antitumor effect of CTLA4 blockade with anti–PD-1 treatment, supporting the potential of a combination immunotherapeutic strategy for brain metastases. Significance: B-cell and CD4+ T follicular helper cell activation via BAFF/APRIL from abundant myeloid cells in the intracranial tumor microenvironment enables a combinatorial effect of CTLA4 and PD-1 blockade in brain metastases.

21 August 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
FMFumiaki Mukohara
Fumiaki Mukohara
KIKazuma Iwata
Kazuma Iwata
TITakamasa Ishino
Takamasa Ishino
TITakashi Inozume
Takashi Inozume
JNJoji Nagasaki
Joji Nagasaki
YTYosuke Togashi
Yosuke Togashi
Immune checkpoint inhibitors (ICIs) exert clinical efficacy against various types of cancers by reinvigorating exhausted CD8 + T cells that can expand and directly attack cancer cells (cancer-specific T cells) among tumor-infiltrating lymphocytes (TILs). Although some reports have identified somatic mutations in TILs, their effect on antitumor immunity remains unclear. In this study, we successfully established 18 cancer-specific T cell clones, which have an exhaustion phenotype, from the TILs of four patients with melanoma. We conducted whole-genome sequencing for these T cell clones and identified various somatic mutations in them with high clonality. Among the somatic mutations, an SH2D2A loss-of-function frameshift mutation and TNFAIP3 deletion could activate T cell effector functions in vitro. Furthermore, we generated CD8 + T cell–specific Tnfaip3 knockout mice and showed that Tnfaip3 function loss in CD8 + T cell increased antitumor immunity, leading to remarkable response to PD-1 blockade in vivo. In addition, we analyzed bulk CD3 + T cells from TILs in additional 12 patients and identified an SH2D2A mutation in one patient through amplicon sequencing. These findings suggest that somatic mutations in TILs can affect antitumor immunity and suggest unique biomarkers and therapeutic targets.

16 December 2025 in Communications Biology
Verified
Journal Article
Open access
PDF file
AMAtsushi Matsuoka
Atsushi Matsuoka
KSKazuhiko Shien
Kazuhiko Shien
STShuta Tomida
Shuta Tomida
MOMasayoshi Ohki
Masayoshi Ohki
KHKazuya Hisamatsu
Kazuya Hisamatsu
STShinichi Toyooka
Shinichi Toyooka
Pulmonary pleomorphic carcinoma (PPC) is a rare subtype of lung cancer that comprises both epithelial and sarcomatoid components. The molecular basis of PPC, including the cellular dynamics of its components, remains largely unknown. To elucidate potential therapeutic targets for PPC, we perform a multi-omics analysis incorporating digital spatial profiling and single-cell RNA sequencing (scRNA-seq). PPC exhibits diverse driver gene alterations, including MET exon 14 skipping mutation (METex14) and ALK fusion. In spatial transcriptomics, MET gene and protein are overexpressed exclusively within the epithelial component and not in the sarcomatoid component, even in patients harboring METex14. Epithelial-mesenchymal transition (EMT)-related transcriptional changes, along with extracellular matrix (ECM) remodeling between the epithelial and sarcomatoid components, are observed. scRNA-seq identifies cell populations within the epithelial component that contribute to the malignant transformation and differentiation of the sarcomatoid component. They are characterized by an intermediate EMT state with ECM remodeling signature, suggesting their potential as novel therapeutic targets for PPC.


17 June 2026
Verified
Other
Open access
TNToshifumi Ninomiya
Toshifumi Ninomiya
NKNaoya Kemmotsu
Naoya Kemmotsu
FMFumiaki Mukohara
Fumiaki Mukohara
MMMasaki Magari
Masaki Magari
AMAi Miyamoto
Ai Miyamoto
YTYosuke Togashi
Yosuke Togashi
Additional data related the effects of anti-PD-1 and anti-CTLA-4 mAbs on TILs

17 June 2026
Verified
Other
Open access
TNToshifumi Ninomiya
Toshifumi Ninomiya
NKNaoya Kemmotsu
Naoya Kemmotsu
FMFumiaki Mukohara
Fumiaki Mukohara
MMMasaki Magari
Masaki Magari
AMAi Miyamoto
Ai Miyamoto
YTYosuke Togashi
Yosuke Togashi
Gating strategy for myeloid cells in flow cytometry analysis